deltatrials
Completed PHASE2/PHASE3 NCT00125203

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis

Sponsor: ALS Association

Conditions Amyotrophic Lateral Sclerosis Sialorrhea
Interventions Botulinum toxin type B (Myobloc) Injection of salivary glands
Updated 5 times since 2017 Last updated: Mar 13, 2012 Started: Jul 31, 2003 Completion: Aug 31, 2007

A PHASE2/PHASE3 clinical study on Amyotrophic Lateral Sclerosis and Sialorrhea, this trial is completed. The trial is conducted by ALS Association and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ALS Association
  • Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System
  • The University of Texas Health Science Center at San Antonio
  • University of Kansas
Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Charlotte, United States
  • • Kansas City, United States